Aligos Therapeutics, Inc.

ALGSNasdaq· Biological Products, (No Diagnostic Substances)

Price History

Revenue

$2.2M

▼ 39.5% YoY

Net Income

-$24.2M

▲ 81.6% YoY

EPS

$-2.45

▲ 88.3% YoY

Cash

$18.3M

▼ 50.5% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.